Indicates growing incidence of cancer among Indian population; five out of top 20 new brand launches are cancer drugs ...

Goldman Sachs updated its price target on AstraZeneca (NASDAQ:AZN:LN) (NASDAQ: AZN) shares to GBP150.67, down from GBP155.58, while reaffirming a Buy rating on the stock. The adjustment follows a ...

LOS ANGELES, CA / ACCESS Newswire / February 8, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

AstraZeneca announced that it could face a fine of up to $4.5 million in China over suspected unpaid import taxes, a figure significantly lower than some investors had feared. The ...

The Anglo-Swedish pharmaceutical giant AstraZeneca faces mounting pressure from shareholders regarding ongoing investigations in China, one of its key markets. The concerns emerged after the detention ...

An estimated 5,000 people in the United States are living with Eosinophilic Granulomatosis with Polyangiitis (EGPA), a rare ...

Cancer researchers are one step closer to developing an effective vaccine to treat people with clear cell renal cell ...

AstraZeneca’s planned vaccine hub for Liverpool is off the table - business editor Karl Matchett and Whitehall editor Kate ...

Global stocks mostly rose Thursday on easing trade tensions, with London and Frankfurt hitting record highs ahead of key US ...

Days after Vancouver’s Aspect Biosystems Ltd. landed US$115 million in Series B financing in early January, CEO Tamer Mohamed likely surprised many by telling BIV that he thought the investment ...

AstraZeneca unveiled both its fourth-quarter and full-year 2024 results before market open today, revealing that its total revenue was $14.89 billion. This represented a meaty 24% improvement over Q4 ...

The boss of drugmaker AstraZeneca has said he was "very disappointed"” with the firm’s move to scrap plans for a £450 million vaccine plant in Liverpool, ...